[
  {
    "ts": null,
    "headline": "HSBC Cuts Zoetis Inc. (ZTS)’s Price Target To $140 From $180, Keeps Buy Rating",
    "summary": "Zoetis Inc. (NYSE:ZTS) is among the 11 Most Oversold S&P 500 Stocks Heading into 2026. On December 10, HSBC slashed its price target on the stock to $140 from $180, as part of the firm’s broader overview of pharmaceutical stocks for 2026. However, the investment bank maintained its earlier Buy rating for the shares. It […]",
    "url": "https://finnhub.io/api/news?id=d6257bd5237b97d7a214aba29582c77253115d1f8adf9f8fe074058a778d9945",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765598329,
      "headline": "HSBC Cuts Zoetis Inc. (ZTS)’s Price Target To $140 From $180, Keeps Buy Rating",
      "id": 137792931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Zoetis Inc. (NYSE:ZTS) is among the 11 Most Oversold S&P 500 Stocks Heading into 2026. On December 10, HSBC slashed its price target on the stock to $140 from $180, as part of the firm’s broader overview of pharmaceutical stocks for 2026. However, the investment bank maintained its earlier Buy rating for the shares. It […]",
      "url": "https://finnhub.io/api/news?id=d6257bd5237b97d7a214aba29582c77253115d1f8adf9f8fe074058a778d9945"
    }
  }
]